Business Description
![VYNE Therapeutics Inc VYNE Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000BDSO.png?14)
VYNE Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US5868581027
Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 477.5 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.66 | |||||
Beneish M-Score | -3.6 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -84.8 | |||||
3-Year EBITDA Growth Rate | 72.7 | |||||
3-Year EPS without NRI Growth Rate | 65.2 | |||||
3-Year FCF Growth Rate | 68.1 | |||||
3-Year Book Growth Rate | -26.1 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.49 | |||||
9-Day RSI | 39.66 | |||||
14-Day RSI | 38.7 | |||||
6-1 Month Momentum % | 6.93 | |||||
12-1 Month Momentum % | -39.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 13.02 | |||||
Quick Ratio | 13.02 | |||||
Cash Ratio | 12.4 | |||||
Days Sales Outstanding | 164.38 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -80.4 | |||||
Shareholder Yield % | -0.62 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -7272.81 | |||||
Net Margin % | -6874.47 | |||||
FCF Margin % | -6582.74 | |||||
ROE % | -63.96 | |||||
ROA % | -54.08 | |||||
ROIC % | -1049.39 | |||||
ROC (Joel Greenblatt) % | -15898.71 | |||||
ROCE % | -65.72 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 22.05 | |||||
PB Ratio | 0.31 | |||||
Price-to-Tangible-Book | 0.31 | |||||
EV-to-EBIT | 1.92 | |||||
EV-to-Forward-EBIT | -0.1 | |||||
EV-to-EBITDA | 1.92 | |||||
EV-to-Forward-EBITDA | -0.1 | |||||
EV-to-Revenue | -139.91 | |||||
EV-to-Forward-Revenue | 0.19 | |||||
EV-to-FCF | 2.13 | |||||
Price-to-Net-Current-Asset-Value | 0.32 | |||||
Price-to-Net-Cash | 0.34 | |||||
Earnings Yield (Greenblatt) % | 52.08 | |||||
FCF Yield % | -104.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VYNE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VYNE Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.423 | ||
EPS (TTM) ($) | -5.689 | ||
Beta | 2.38 | ||
Volatility % | 77.73 | ||
14-Day RSI | 38.7 | ||
14-Day ATR ($) | 0.201066 | ||
20-Day SMA ($) | 2.046 | ||
12-1 Month Momentum % | -39.01 | ||
52-Week Range ($) | 1.57 - 6.7892 | ||
Shares Outstanding (Mil) | 14.53 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
VYNE Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
VYNE Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
VYNE Therapeutics Inc Frequently Asked Questions
What is VYNE Therapeutics Inc(VYNE)'s stock price today?
The current price of VYNE is $1.83. The 52 week high of VYNE is $6.79 and 52 week low is $1.57.
When is next earnings date of VYNE Therapeutics Inc(VYNE)?
The next earnings date of VYNE Therapeutics Inc(VYNE) is 2024-08-14 Est..
Does VYNE Therapeutics Inc(VYNE) pay dividends? If so, how much?
VYNE Therapeutics Inc(VYNE) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |